Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
05 août 2009 08h05 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - August 5, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) and Marshall Edwards, Inc. (NASDAQ: MSHL) have
concluded a license agreement for...
Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial
17 juin 2009 08h30 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - June 17, 2009) - The Independent Data Monitoring Committee
(IDMC) created to oversee the conduct of the Phase III OVArian TUmor
REsponse (OVATURE) Trial, which convened...
Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial
14 avr. 2009 08h20 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 14, 2009) - Marshall Edwards,
Inc., (NASDAQ: MSHL) today announced that it will be undertaking an
un-blinded analysis of the data from its...
Board Changes at Novogen Limited Announced
23 mars 2009 10h46 HE
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 23, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is pleased to announce the appointment of Mr. William
D. Rueckert to its Board of...
Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc.
19 mars 2009 13h07 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 19, 2009) - Marshall Edwards, Inc.
(NASDAQ: MSHL) is pleased to announce the appointment of Leah Cann to the
Board of Directors of the...
Yale Researchers Present Results of Phase II Phenoxodiol Clinical Trial in Prostate Cancer Patients at ASCO 2009 Genitourinary Cancers Symposium
24 févr. 2009 08h00 HE
|
Marshall Edwards, Inc.
ORLANDO, FL--(Marketwire - February 24, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) --
Preliminary results from a Phase II clinical trial of oral phenoxodiol in
patients with prostate cancer to be...
Marshall Edwards, Inc. to Present at the 27th Annual JPMorgan Healthcare Conference
14 janv. 2009 08h59 HE
|
Marshall Edwards, Inc.
WASHINGTON, DC--(Marketwire - January 14, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) will
present at the 27th Annual JPMorgan Healthcare Conference in San Francisco
on Thursday January 15, 2008 at...
Marshall Edwards, Inc. Granted IND for Triphendiol
07 janv. 2009 08h10 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - January 7, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) today
announced that it has been granted an Investigative New Drug (IND) approval
by the United States Food and...
Marshall Edwards, Inc. Announces Resignation of Stephen Breckenridge From Board of Directors and Appointment of William Rueckert as Chairman of Audit Committee
19 déc. 2008 08h15 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - December 19, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL)
announced that Stephen Breckenridge resigned as a member of the Board of
Directors effective December 15, 2008...
Marshall Edwards, Inc. Files IND Application for Triphendiol
01 déc. 2008 08h10 HE
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - December 1, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL) today
announced that it has filed an application with the United States Food and
Drug Administration for an...